about
Weight reduction is not a major reason for improvement in rheumatoid arthritis from lacto-vegetarian, vegan or Mediterranean dietsFat intake and composition of fatty acids in serum phospholipids in a randomized, controlled, Mediterranean dietary intervention study on patients with rheumatoid arthritis.The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritisCalibration of the PROMIS physical function item bank in Dutch patients with rheumatoid arthritis.Inverse association between air pressure and rheumatoid arthritis synovitis.Regulatory B cells are inversely associated with disease activity in rheumatoid arthritisApplying science in practice: the optimization of biological therapy in rheumatoid arthritis.Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis.Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis.Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefitIs DAS28 an appropriate tool to assess remission in rheumatoid arthritis?Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results.Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study.Consensus statement on the use of rituximab in patients with rheumatoid arthritisHeterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH).Increased Kappa/Lambda Hybrid Antibody in Serum Is a Novel Biomarker Related to Disease Activity and Inflammation in Rheumatoid ArthritisInflammatory arthritis: an overview for primary care physicians.Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritisSafety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis.Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients.Quality indicators in rheumatoid arthritis: results from the METEOR database.The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis.Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis.DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt.Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.Patient self-assessment and physician's assessment of rheumatoid arthritis activity: which is more realistic in remission status? A comparison with ultrasonography.Decreased Expression of Sphingosine-1-Phosphate Receptor 1 in the Blood Leukocyte of Rheumatoid Arthritis Patients
P2860
Q24811469-24CD693D-F11D-477D-9729-BC84FE9E9EC5Q24811536-80AAF4EF-E4BB-4D85-9B26-BAD7DBB90344Q30576366-DF0262EF-6FF3-4173-AEBB-178952A32F03Q33456382-B2A941B3-C9D0-4006-9C85-929F1FE41F06Q33460596-B1B2B293-F9CE-4735-9012-78AFD1CE9ABCQ33941664-0A505594-2123-4288-AF66-79248C65FD8FQ34613898-D10B0ABE-98F2-4331-8237-A7CF3327B378Q34637048-92F49978-56B1-40BA-87C2-3C4BDB041CF7Q35552423-73199419-B6BF-4BF4-A16D-8B1340983AA6Q35553008-9F8BABF7-7E95-48AD-A8AF-BD25CB23AE02Q35553775-001E3242-A9E8-47B1-96B0-E84334354C89Q35554765-D0941113-5297-4C0C-B7BB-0CD0F80CF835Q35554892-C5757FD6-378C-4786-A610-632E425816ACQ35637990-EE223376-E442-4F3C-AEA5-6744478E8F88Q35638676-D35EF0CB-D2A1-493C-9F50-CC3FA1E29F5DQ35753598-3DEB4951-1D43-4268-B289-705A9CE2831FQ36814592-5E359745-21AF-4429-ABA8-77E3BEF0531AQ37427257-4180D1DD-78BB-40EB-9A54-67A100108D9BQ37622219-D91ECC9E-CFDD-4C03-B889-10E02148DF32Q38753455-656932E8-5575-4C0E-87D8-B7D18FA02A04Q39245507-A61F8F6A-882C-4011-A1DC-840C6D925E94Q41067618-FB1A8954-DD02-4EDF-913B-C502E06AFC0FQ41530781-F1EFF805-98F4-4F73-851B-B1C5D744563CQ42685943-987C914C-34B6-419B-BABC-EFD95E4B405DQ43019736-D54137C7-D9DB-421A-9BD4-43C741345024Q45734541-CD9FC1D3-5271-48CB-8D0B-28B450578011Q45790066-64D92E2C-C867-46B6-965D-6DF963976803Q53126565-ACB21E05-A025-4EF6-AFD4-22A8B4791F77Q58543113-3809FD31-3CF9-4C4A-83B5-60E737A25AA4
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Clinical outcome measures in rheumatoid arthritis.
@ast
Clinical outcome measures in rheumatoid arthritis.
@en
Clinical outcome measures in rheumatoid arthritis.
@nl
type
label
Clinical outcome measures in rheumatoid arthritis.
@ast
Clinical outcome measures in rheumatoid arthritis.
@en
Clinical outcome measures in rheumatoid arthritis.
@nl
prefLabel
Clinical outcome measures in rheumatoid arthritis.
@ast
Clinical outcome measures in rheumatoid arthritis.
@en
Clinical outcome measures in rheumatoid arthritis.
@nl
P2860
P1476
Clinical outcome measures in rheumatoid arthritis.
@en
P2093
van Gestel AM
van Riel PL
P2860
P304
P356
10.1136/ARD.59.SUPPL_1.I28
P407
P478
59 Suppl 1
P577
2000-11-01T00:00:00Z